Form 4: Stryker Director Andrew Silvernail Receives RSU Grant

Stryker Corporation Director Andrew K. Silvernail was granted 762 restricted stock units as part of his board compensation.

Summary

• Director Andrew K. Silvernail received a grant of 762 Restricted Stock Units (RSUs) on May 6, 2026.
• Each RSU represents a contingent right to receive one share of Stryker Common Stock.
• The RSUs vest on the earlier of the 2027 Annual Meeting of Shareholders or May 6, 2027.
• The director has elected to defer receipt of the underlying shares until his departure from the Board of Directors.
• Following this transaction, the director's total beneficial ownership is 18,465 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Director alignment with long-term shareholder interests through equity-based compensation.
• Voluntary deferral of share receipt indicates long-term commitment to the company.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership in a publicly traded company.

Future Outlook

The RSUs are scheduled to vest in May 2027, with the director deferring receipt of the shares until his eventual departure from the Board.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the medical technology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with compensation practices at peer medical device companies like Medtronic and Boston Scientific.
• The deferral election is a common practice among board members to align personal wealth with long-term corporate outcomes.

Stakeholder Impact

• Minimal impact on shareholders as the grant represents a standard component of director compensation.

Next Steps

• Vesting of RSUs on or before May 6, 2027.

Key Dates

Keywords

Stryker, SYK, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation